General discussion, page-13308

so doing a bit more reading, seems the split was to seperate the canabis ip from the covid and oncology ip. this seem correct @comincon ? the previous valuation seems pretty mind blowing. axim is only valued 17m now. i cant get access to sec filings pre 2017 to see what caused the run up in value but it must have been something substantial to sustain that for 2 years. i assume it was oncology related that caused it. the split in 2018 seems to have contributed considerably to the decline in mc, which obviously makes sense but still doesnt add up how the current value for APIRx is under 100mil.